Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sacituzumab govitecan before radical cystectomy in cisplatin-ineligible or cisplatin-refusing MIBC
2024-515301-26-00Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in muscle-invasive bladder carcinoma (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Complete pathological response rate. Started Oct 2024; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
muscle-invasive bladder carcinoma (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-515301-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515301-26-00.